We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sativex

News List

UK trial to assess Sativex for the treatment of ‘aggressive’ brain tumours pharmatimes
August 06, 2021
A new UK-based trial is set to assess the efficacy of GW Pharma’s cannabis-based drug Sativex as a potential treatment for patients with a recurrent glioblastoma – the most aggressive form of brain tumours.
GW Pharma begins recruitment for US-based Sativex trial pharmatimes
November 06, 2020
GW Pharmaceuticals has initiated the first US phase III clinical trial studying nabiximols for multiple sclerosis (MS) associated spasticity.
GW Pharma regains Sativex rights in UK pharmatimes
March 06, 2020
GW Pharmaceuticals has regained the rights to the commercialisation of Sativex (nabiximols) in the UK, taking the reins back from Bayer.